Policy Brief Series:
Closing Gaps in Women’s Health: The Cumulative Impact of Sex Bias from Cells to Society
Executive Summary
On average, women spend about a quarter more of their lives in poor health than men, a gap usually framed as a downstream problem of access or behaviour [1]. We argue that it begins far earlier, in the methods of biomedical science itself. Viewed through an epidemiological lens, a male-default assumption produces a compounding bias across four connected layers of the women’s health ecosystem: preclinical research, where male animals and sex-unlabelled cell lines undermine internal validity; clinical trials, where the underrepresentation of women and the failure to analyse by sex undermine external validity; clinical practice, where male-calibrated criteria drive misdiagnosis and poorer outcomes; and the neglected environmental exposome, where exposures and biological responses differ by sex yet are rarely studied. Treating biological sex as a fundamental determinant, rather than a nuisance variable, is a prerequisite for rigorous science and equitable care. We call on research funders, regulators, journals and editorial boards, professional societies, health systems, and global health bodies to take the concrete actions set out below.
Context and importance of the problem
A biased evidentiary foundation does not stay contained. Assumptions built into preclinical models flow upstream into clinical trial design, into the diagnostic criteria and treatment algorithms used at the bedside, and ultimately into the quality of care women receive. Running alongside this pipeline is a fourth, largely uncharacterised dimension: the environmental exposome, where sex and gender shape both exposure and biological response. The sections below summarise key dimensions of this cumulative bias. They are not intended as a comprehensive review, but as an evidence-anchored basis for coordinated action across the research, regulatory, clinical, and environmental-health communities.
Preclinical research: internal validity
Despite the 2014 policy to balance sex in cell and animal studies [2], male-only research continues to outnumber female-only research, and the sex origin of cell lines is frequently ignored even though cellular sex influences biological pathways [6]. In cardiology, one systematic review found that 71.6% of preclinical studies used only male subjects [4]; in neuroscience, male-only studies remain several times more common than female-only studies [5]. This is consequential because disease prevalence follows sex-specific patterns, with women at higher lifetime risk of conditions such as Alzheimer’s disease and depression. Inclusion has improved since sex-as-a-biological-variable policies were introduced, but sex-disaggregated analysis has stalled: only around 42% of studies enrolling both sexes actually analyse data by sex, a decline from earlier levels [3]. Studies led by women are markedly more likely to include and analyse female models, indicating that the demographics of the scientific workforce are themselves a determinant of rigour [7]. The downstream cost is real: most drugs withdrawn from the market for safety reasons posed greater health risks to women [8].
Clinical trials: external validity
Women were historically excluded from early-phase trials until regulatory reversals in the 1990s, yet underrepresentation persists in high-burden specialties such as oncology, neurology, immunology, and nephrology [9]. Women account for around 60% of those living with psychiatric disorders but only 42% of participants in recent psychiatric trials [10]. Pregnant and breastfeeding individuals remain routinely excluded, creating an evidence vacuum that the draft ICH E21 guideline now seeks to address through a presumption of inclusion. Crucially, enrolling both sexes is not sufficient: when outcomes are not analysed by sex, clinically important differences in efficacy and adverse effects remain hidden [11].
Clinical practice: diagnosis, treatment, and funding
Diagnostic criteria calibrated to male presentations drive delayed and missed diagnoses. Girls and women with ADHD are diagnosed later and less often than boys and men [12]; women presenting with cardiovascular disease are more likely to be misdiagnosed and undertreated [13]; and women with Alzheimer’s disease can experience more rapid cognitive decline despite being assessed with criteria not tailored to them [14]. Sex differences extend to disease biology, treatment response, and toxicity, as seen in cancers where women may face worse survival and distinct treatment-related harms [15]. Research investment compounds these gaps: conditions that disproportionately affect women, including migraine, endometriosis, and mental and musculoskeletal disorders, are underfunded relative to their burden [16]. Evidence synthesis carries the bias forward, as most systematic reviews still fail to report results by sex [17].
The environmental exposome: the neglected dimension
Environmental exposures are modifiable determinants of health, acting through interactions between genes, hormones, the microbiome, and external agents [18]. Yet sex and gender are seldom integrated into environmental epidemiology. Exposure patterns differ markedly by sex and gender: chemicals in personal care products have been linked to altered pubertal timing and breast cancer risk [19], while occupational and domestic exposures concentrated in female-dominated and unpaid work, such as cleaning agents and indoor combustion, remain under-studied and under-regulated [20]. Climate change imposes a double burden on women, combining physiological vulnerability, for example to extreme heat, with social vulnerability such as poverty, caregiving, and food insecurity, yet adaptation policy rarely accounts for these differences [21].
Current policy options
Important mandates already exist, including funder requirements to consider sex as a biological variable, regulatory expectations for the inclusion of women, the draft ICH E21 guideline on pregnant and breastfeeding populations, and the Cochrane Sex/Gender Methods Group. The persistent problem is not the absence of principles but the weakness of enforcement, the neglect of analysis as distinct from inclusion, and the under-use of structural levers such as leadership diversity and editorial standards. The recommendations below are designed to convert existing aspirations into enforceable, measurable practice.
Policy Recommendations
INEP recommends that funders, regulators, journals, professional societies, and health systems:
Mandate sex-stratified reporting and analysis, not merely inclusion, across preclinical and clinical research, and require testing for interaction rather than simply controlling for sex.
Require the sex-typing of cell lines and treat “unknown sex” as missing data that compromises reproducibility.
Require an epidemiological justification, in grant applications, for the sex distribution of animal and cell models.
Align trial enrolment with the sex-specific burden of disease, especially in high-gap specialties, and make regulatory approval contingent on sex-stratified analyses.
Adopt a presumption of inclusion for pregnant and breastfeeding individuals, in line with the draft ICH E21 guideline, and strengthen post-marketing pharmacovigilance.
Revise diagnostic criteria and clinical guidelines to incorporate female-specific presentations and move beyond sex-neutral treatment where biological evidence exists.
Realign research funding with burden of disease through periodic burden-of-disease audits.
Make sex-stratified analysis standard in environmental health research, and integrate the gendered exposome into exposure assessment and climate adaptation planning.
Track research-team and leadership diversity as a quality metric, and train peer reviewers and editors to identify sex-blind methodology.
Harmonise regulatory standards internationally to ensure consistent protection and prevent the migration of less rigorous practices across jurisdictions.
ENDORSEMENTS (as of November 2026)
REFERENCES
1. Ellingrud K, et al. Closing the women’s health gap: a US$1 trillion opportunity. McKinsey Health Institute/World Economic Forum; 2024.
2. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282-3.
3. Woitowich NC, Beery A, Woodruff T, King MM. A 10-year follow-up study of sex inclusion in the biological sciences. eLife. 2020;9:e56344.
4. Ramirez FD, et al. Sex bias is increasingly prevalent in preclinical cardiovascular research. Circulation. 2017;135(6):625-6.
5. Rechlin RK, Splinter TF, Hodges TE, Albert AY, Galea LA. An analysis of neuroscience and psychiatry papers outlines opportunities for increasing discovery of sex differences. Nat Commun. 2022;13:2137.
6. Nunes LM, et al. The gender of cell lines matters when screening for novel anti-cancer drugs. AAPS J. 2014;16(4):872-4.
7. Labinaz A, Marbach JA, Jung RG. Female authorship in preclinical cardiovascular research. JACC Basic Transl Sci. 2019;4:471-7.
8. US Government Accountability Office. Drug safety: most drugs withdrawn in recent years had greater health risks for women. GAO-01-286R; 2001.
9. Steinberg JR, et al. Female enrollment and participant sex by burden of disease in US clinical trials, 2000-2020. JAMA Netw Open. 2021;4(6):e2113749.
10. Sosinsky AZ, et al. Enrollment of female participants in US phase 1-3 clinical trials, 2016-2019. Contemp Clin Trials. 2022;115:106718.
11. Au M, et al. A systematic review of sex-specific reporting in heart failure clinical trials. JACC Adv. 2022;1(4):100079.
12. Martin J. Why are females less likely to be diagnosed with ADHD in childhood than males? Lancet Psychiatry. 2024;11(4):303-10.
13. Burgess SN. Sex-based disparities in cardiovascular medicine. Circ Cardiovasc Interv. 2022;15(2):e011714.
14. Ferretti MT, et al. Sex and gender differences in Alzheimer’s disease. Eur J Neurol. 2020;27(6):928-43.
15. Toren P, et al. The sex gap in bladder cancer survival: a missing link in bladder cancer care? Nat Rev Urol. 2024;21(3):181-92.
16. Patwardhan V, et al. Differences between females and males in the top 20 causes of disease burden globally. Lancet Public Health. 2024;9(5):e282-94.
17. Antequera A, et al. Lack of sex-related analysis and reporting in Cochrane Reviews. Syst Rev. 2022;11(1):281.
18. Motsinger-Reif AA, et al. Gene-environment interactions within a precision environmental health framework. Cell Genomics. 2024;4(7).
19. Rivera-Núñez Z, et al. Phenols, parabens, phthalates and puberty: a systematic review. Curr Environ Health Rep. 2022;9(4):517-34.
20. Salonen H, et al. Cleaning products: their chemistry, effects on indoor air quality, and implications for human health. Environ Int. 2024;108836.
21. Anjum G, Aziz M. Climate change and gendered vulnerability: a systematic review of women’s health. Womens Health (Lond). 2025;21:17455057251323645.
Authors: Keren Agay-Shay, Elisa Chilet-Rosell, Priya Bahri, and Jacqueline H Stephens, with input and endorsement from the INEP Board
15 September 2026